I think what the potential efficacy of GLP-1 agonists for substance-use disorders is telling us, is suggesting is that there may be this kind of final common pathway, this core underlying biology of desire, of wanting things that may transcend food or alcohol or other things and may reflect something fundamental about the way the brain processes these feelings
In appropriate patients, medically supervised GLP-1 therapy has been associated with: Sustained weight reduction over time Improvements in A1C and overall blood sugar in people with type 2 diabetes Reduced waist circumference and visceral fat Better blood pressure, cholesterol, and other metabolic markers In some studies with Wegovy, a reduced risk of certain serious cardiovascular events in adults with obesity and existing heart disease At NuIQ, the goal of our GLP-1 semaglutide program is not just fast weight lossits sustainable weight management, better energy, and long-term metabolic health, all under the guidance of licensed medical professionals
The reasons for excluding these studies are detailed in Supplementary Table 2
GLP-1 therapy is most effective for individuals who: Have a BMI of 30 or higher, or a BMI of 27 or higher with obesity-related conditions
Mumm S, Jones J, Finnegan P, Whyte MP
